Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Zanubrutinib

FDA-approved product (capsule, oral), marketed as Brukinsa.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Zanubrutinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Mantle cell lymphoma
  • Neoplasm
  • Waldenstrom macroglobulinemia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Bruton's tyrosine kinase (btk) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis51.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Zanubrutinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-10.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Zanubrutinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors

    NCT05887726 · start 2023-08-01

    Registered record
    Registry ID
    NCT05887726
    Conditions
    Diffuse Large B Cell Lymphoma
    Interventions
    Zanubrutinib; Rituximab; Cyclophosphamide; Epirubicin; Vincristine; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2023-08-01
    Completion
    2025-08-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiffuse Large B Cell Lymphoma
    InterventionZanubrutinib; Rituximab; Cyclophosphamide; Epirubicin +2 more
    PhasePhase 2
    Registry statusUnknown

  • Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma

    NCT05940051 · start 2023-07-20

    Registered record
    Registry ID
    NCT05940051
    Conditions
    Diffuse Large B Cell Lymphoma
    Interventions
    Zanubrutinib, Polatuzumab vedotin and Rituximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2023-07-20
    Completion
    2025-12-30
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiffuse Large B Cell Lymphoma
    InterventionZanubrutinib, Polatuzumab vedotin and Rituximab
    PhasePhase 2
    Registry statusUnknown

  • Relative Bioavailability of Zanubrutinib Tablets Compared to Capsules and Effects of Food on the Pharmacokinetics of the Tablet in Healthy Adults

    NCT05547399 · start 2022-06-07

    Registered record
    Registry ID
    NCT05547399
    Conditions
    Healthy Volunteers
    Interventions
    Zanubrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-06-07
    Completion
    2022-12-07
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionZanubrutinib
    PhasePhase 1
    Registry statusCompleted

  • An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients

    NCT05356858 · start 2022-05-07

    Registered record
    Registry ID
    NCT05356858
    Conditions
    Neuromyelitis Optica
    Interventions
    zanubrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2022-05-07
    Completion
    2024-02-24
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuromyelitis Optica
    Interventionzanubrutinib
    PhasePhase 2
    Registry statusTerminated

  • Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma

    NCT05326308 · start 2022-04-26

    Registered record
    Registry ID
    NCT05326308
    Conditions
    Waldenström's Macroglobulinemia; Chronic Lymphocytic Leukemia; Marginal Zone Lymphoma; Follicular Lymphoma
    Interventions
    Zanubrutinib; Obinutuzumab
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2022-04-26
    Completion
    2028-08
    Enrolment
    845

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionWaldenström's Macroglobulinemia; Chronic Lymphocytic Leukemia; Marginal Zone Lymphoma; Follicular Lymphoma
    InterventionZanubrutinib; Obinutuzumab
    PhaseNot recorded
    Registry statusRecruiting

  • Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL

    NCT05287984 · start 2022-03-22

    Registered record
    Registry ID
    NCT05287984
    Conditions
    Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Newly Diagnosed
    Interventions
    Zanubrutinib, Fludarabine, cyclophosphamide and rituximab; Zanubrutinib, bendamustine, rituximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2022-03-22
    Completion
    2024-11-29
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Newly Diagnosed
    InterventionZanubrutinib, Fludarabine, cyclophosphamide and rituximab; Zanubrutinib, bendamustine, rituximab
    PhasePhase 2
    Registry statusUnknown

  • Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

    NCT05168930 · start 2022-02-18

    Registered record
    Registry ID
    NCT05168930
    Conditions
    Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)
    Interventions
    Venetoclax; Zanubrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2022-02-18
    Completion
    2028-10-28
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)
    InterventionVenetoclax; Zanubrutinib
    PhasePhase 2
    Registry statusRecruiting

  • Zanubrutinib for HLH

    NCT05320575 · start 2022-02-01

    Registered record
    Registry ID
    NCT05320575
    Conditions
    HLH
    Interventions
    Zanubrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2022-02-01
    Completion
    2023-08-01
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHLH
    InterventionZanubrutinib
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia

    NCT05199909 · start 2022-01-25

    Registered record
    Registry ID
    NCT05199909
    Conditions
    Antiphospholipid Syndrome; Thrombocytopenia; Treatment
    Interventions
    zanubrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2022-01-25
    Completion
    2025-06-30
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntiphospholipid Syndrome; Thrombocytopenia; Treatment
    Interventionzanubrutinib
    PhasePhase 2
    Registry statusRecruiting

  • Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

    NCT04840602 · start 2022-01-05

    Registered record
    Registry ID
    NCT04840602
    Conditions
    Lymphoplasmacytic Lymphoma; Waldenstrom Macroglobulinemia
    Interventions
    Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Computed Tomography; Ibrutinib; Positron Emission Tomography; Rituximab; Venetoclax; Zanubrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2022-01-05
    Completion
    2028-03-31
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoplasmacytic Lymphoma; Waldenstrom Macroglobulinemia
    InterventionBiospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Computed Tomography +5 more
    PhasePhase 2
    Registry statusRecruiting

  • Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma

    NCT04938297 · start 2021-05-26

    Registered record
    Registry ID
    NCT04938297
    Conditions
    Central Nervous System Lymphoma
    Interventions
    Rituximab, Lenalidomide, Zanubrutinib; Lenalidomide, Zanubrutinib; Lenalidomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2021-05-26
    Completion
    2025-12-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCentral Nervous System Lymphoma
    InterventionRituximab, Lenalidomide, Zanubrutinib; Lenalidomide, Zanubrutinib; Lenalidomide
    PhasePhase 2
    Registry statusUnknown

  • Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma

    NCT04668365 · start 2020-12-25

    Registered record
    Registry ID
    NCT04668365
    Conditions
    Diffuse Large B Cell Lymphoma; CD79A Gene Mutation; CD79B Gene Mutation
    Interventions
    Rituximab; Zanubrutinib; Cyclophosphamide; Epirubicin; Vincristine; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Suspended
    Start
    2020-12-25
    Completion
    2025-12-25
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiffuse Large B Cell Lymphoma; CD79A Gene Mutation; CD79B Gene Mutation
    InterventionRituximab; Zanubrutinib; Cyclophosphamide; Epirubicin +2 more
    PhasePhase 2
    Registry statusSuspended

  • Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

    NCT04436107 · start 2020-09-11

    Registered record
    Registry ID
    NCT04436107
    Conditions
    Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Interventions
    Zanubrutinib; Lenalidomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-09-11
    Completion
    2024-03-28
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed/Refractory Diffuse Large B-Cell Lymphoma
    InterventionZanubrutinib; Lenalidomide
    PhasePhase 1
    Registry statusCompleted

  • Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    NCT04458610 · start 2020-05-26

    Registered record
    Registry ID
    NCT04458610
    Conditions
    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Interventions
    Rituximab; Zanubrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2020-05-26
    Completion
    2027-05-26
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    InterventionRituximab; Zanubrutinib
    PhasePhase 2
    Registry statusActive not recruiting

  • A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

    NCT03734016 · start 2018-11-01

    Registered record
    Registry ID
    NCT03734016
    Conditions
    Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    Interventions
    Zanubrutinib; Ibrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-11-01
    Completion
    2024-02-28
    Enrolment
    652

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    InterventionZanubrutinib; Ibrutinib
    PhasePhase 3
    Registry statusCompleted